Dataset Information

Interaction of Avibactam with Class B Metallo-?-Lactamases.

ABSTRACT: ?-Lactamases are the most important mechanisms of resistance to the ?-lactam antibacterials. There are two mechanistic classes of ?-lactamases: the serine ?-lactamases (SBLs) and the zinc-dependent metallo-?-lactamases (MBLs). Avibactam, the first clinically useful non-?-lactam ?-lactamase inhibitor, is a broad-spectrum SBL inhibitor, which is used in combination with a cephalosporin antibiotic (ceftazidime). There are multiple reports on the interaction of avibactam with SBLs but few such studies with MBLs. We report biochemical and biophysical studies on the binding and reactivity of avibactam with representatives from all 3 MBL subfamilies (B1, B2, and B3). Avibactam has only limited or no activity versus MBL-mediated resistance in pathogens. Avibactam does not inhibit MBLs and binds only weakly to most of the MBLs tested; in some cases, avibactam undergoes slow hydrolysis of one of its urea N-CO bonds followed by loss of CO2, in a process different from that observed with the SBLs studied. The results suggest that while the evolution of MBLs that more efficiently catalyze avibactam hydrolysis should be anticipated, pursuing the development of dual-action SBL and MBL inhibitors based on the diazabicyclooctane core of avibactam may be productive.

SUBMITTER: Abboud MI

PROVIDER: S-EPMC5038302 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Interaction of Avibactam with Class B Metallo-β-Lactamases.

Abboud Martine I MI Damblon Christian C Brem Jürgen J Smargiasso Nicolas N Mercuri Paola P Gilbert Bernard B Rydzik Anna M AM Claridge Timothy D W TD Schofield Christopher J CJ Frère Jean-Marie JM

Antimicrobial agents and chemotherapy 20160923 10

β-Lactamases are the most important mechanisms of resistance to the β-lactam antibacterials. There are two mechanistic classes of β-lactamases: the serine β-lactamases (SBLs) and the zinc-dependent metallo-β-lactamases (MBLs). Avibactam, the first clinically useful non-β-lactam β-lactamase inhibitor, is a broad-spectrum SBL inhibitor, which is used in combination with a cephalosporin antibiotic (ceftazidime). There are multiple reports on the interaction of avibactam with SBLs but few such studi ...[more]

PMID: 27401561

Similar Datasets

Project description:?-Lactamase enzymes (EC 3.5.2.6) are a significant threat to the continued use of ?-lactam antibiotics to treat infections. A novel non-?-lactam ?-lactamase inhibitor with activity against many class A and C and some class D ?-lactamase variants, avibactam, is now available in the clinic in partnership with ceftazidime. Here, we explored the activity of avibactam against a variety of characterized isogenic laboratory constructs of ?-lactamase inhibitor-resistant variants of the class A enzyme SHV (M69I/L/V, S130G, K234R, R244S, and N276D). We discovered that the S130G variant of SHV-1 shows the most significant resistance to inhibition by avibactam, based on both microbiological and biochemical characterizations. Using a constant concentration of 4 mg/liter of avibactam as a ?-lactamase inhibitor in combination with ampicillin, the MIC increased from 1 mg/liter for blaSHV-1 to 256 mg/liter for blaSHV S130G expressed in Escherichia coli DH10B. At steady state, the k2/K value of the S130G variant when inactivated by avibactam was 1.3 M(-1) s(-1), versus 60,300 M(-1) s(-1) for the SHV-1 ?-lactamase. Under timed inactivation conditions, we found that an approximately 1,700-fold-higher avibactam concentration was required to inhibit SHV S130G than the concentration that inhibited SHV-1. Molecular modeling suggested that the positioning of amino acids in the active site of SHV may result in an alternative pathway of inactivation when complexed with avibactam, compared to the structure of CTX-M-15-avibactam, and that S130 plays a role in the acylation of avibactam as a general acid/base. In addition, S130 may play a role in recyclization. As a result, we advance that the lack of a hydroxyl group at position 130 in the S130G variant of SHV-1 substantially slows carbamylation of the ?-lactamase by avibactam by (i) removing an important proton acceptor and donator in catalysis and (ii) decreasing the number of H bonds. In addition, recyclization is most likely also slow due to the lack of a general base to initiate the process. Considering other inhibitor-resistant mechanisms among class A ?-lactamases, S130 may be the most important amino acid for the inhibition of class A ?-lactamases, perhaps even for the novel diazabicyclooctane class of ?-lactamase inhibitors.

Dataset Information

Interaction of Avibactam with Class B Metallo-?-Lactamases.

Publications

Interaction of Avibactam with Class B Metallo-β-Lactamases.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets